CN113966330B - Plk4抑制剂的晶型s4 - Google Patents

Plk4抑制剂的晶型s4 Download PDF

Info

Publication number
CN113966330B
CN113966330B CN202080030678.8A CN202080030678A CN113966330B CN 113966330 B CN113966330 B CN 113966330B CN 202080030678 A CN202080030678 A CN 202080030678A CN 113966330 B CN113966330 B CN 113966330B
Authority
CN
China
Prior art keywords
cancer
compound
fumarate salt
crystalline form
fumaric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080030678.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113966330A (zh
Inventor
李诗韵
M·R·布莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN113966330A publication Critical patent/CN113966330A/zh
Application granted granted Critical
Publication of CN113966330B publication Critical patent/CN113966330B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080030678.8A 2019-04-24 2020-04-23 Plk4抑制剂的晶型s4 Active CN113966330B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837858P 2019-04-24 2019-04-24
US62/837,858 2019-04-24
PCT/CA2020/050535 WO2020215155A1 (en) 2019-04-24 2020-04-23 Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate

Publications (2)

Publication Number Publication Date
CN113966330A CN113966330A (zh) 2022-01-21
CN113966330B true CN113966330B (zh) 2024-09-13

Family

ID=72940551

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030678.8A Active CN113966330B (zh) 2019-04-24 2020-04-23 Plk4抑制剂的晶型s4

Country Status (16)

Country Link
US (1) US12325700B2 (https=)
EP (1) EP3959209A4 (https=)
JP (1) JP7705351B2 (https=)
KR (1) KR20220004102A (https=)
CN (1) CN113966330B (https=)
AU (1) AU2020264143A1 (https=)
BR (1) BR112021021106A2 (https=)
CA (1) CA3137191A1 (https=)
EA (1) EA202192903A1 (https=)
IL (1) IL287394A (https=)
MA (1) MA55767A (https=)
MX (1) MX2021012993A (https=)
SA (1) SA521430647B1 (https=)
SG (1) SG11202111003UA (https=)
TW (1) TWI862582B (https=)
WO (1) WO2020215155A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7717842B2 (ja) 2021-05-11 2025-08-04 オリック ファーマシューティカルズ，インク． ポロ様キナーゼ４阻害剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764899A (zh) * 2013-10-18 2016-07-13 大学健康网络 Plk-4抑制剂的盐和晶型

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
EP2205241B1 (en) 2007-09-25 2014-05-21 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
US8586598B2 (en) 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
ES2706066T3 (es) 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
US20140051679A1 (en) 2011-10-12 2014-02-20 Univeristy Health Networks Kinase inhibitors and method of treating cancer with same
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764899A (zh) * 2013-10-18 2016-07-13 大学健康网络 Plk-4抑制剂的盐和晶型

Also Published As

Publication number Publication date
BR112021021106A2 (pt) 2021-12-14
WO2020215155A8 (en) 2020-11-26
TW202104216A (zh) 2021-02-01
JP7705351B2 (ja) 2025-07-09
KR20220004102A (ko) 2022-01-11
TWI862582B (zh) 2024-11-21
SA521430647B1 (ar) 2024-01-27
MX2021012993A (es) 2021-12-10
MA55767A (fr) 2022-03-02
IL287394A (en) 2021-12-01
US12325700B2 (en) 2025-06-10
WO2020215155A1 (en) 2020-10-29
EP3959209A4 (en) 2022-12-28
AU2020264143A1 (en) 2021-10-28
EA202192903A1 (ru) 2022-02-09
CA3137191A1 (en) 2020-10-29
EP3959209A1 (en) 2022-03-02
SG11202111003UA (en) 2021-11-29
US20220204494A1 (en) 2022-06-30
CN113966330A (zh) 2022-01-21
JP2022530028A (ja) 2022-06-27

Similar Documents

Publication Publication Date Title
WO2020147838A1 (zh) 一种egfr抑制剂的盐、晶型及其制备方法
EP3502103B1 (en) Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor
CN110577533A (zh) 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
EP4495109A1 (en) Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof
EP4359400B1 (en) Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer
CN112010839B (zh) 靶向丝/苏氨酸激酶抑制剂的晶型
CN113966330B (zh) Plk4抑制剂的晶型s4
US11878980B2 (en) Solid forms of TTK inhibitor
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
TWI436988B (zh) ７-〔（３-氯-６，１１-二氫-６-甲基二苯并〔ｃ，ｆ〕〔１，２〕噻氮呯-１１-基）胺〕庚酸ｓ，ｓ二氧化物之多晶型及其製造與使用方法
CN107849051A (zh) 取代的氨基吡喃衍生物的晶型
CN105732642B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN116023394B (zh) 三环类激酶抑制剂的晶型
JP7822477B2 (ja) Ｒｅｔ阻害剤であるセルペルカチニブの結晶形態ａの調製方法
EP4653445A1 (en) Cdk inhibitor and crystal form of pharmaceutically acceptable salt thereof, and use thereof
EA044843B1 (ru) Кристаллическая форма ингибитора plk4
CN120383595A (zh) 抑制cdk4/6活性化合物的半l-酒石酸盐一水合物
CN117466898A (zh) 氨基吡唑并嘧啶化合物的晶体
JP2024508497A (ja) 医薬組成物、その製造方法及び使用
WO2023006057A1 (zh) 氨基吡唑并嘧啶化合物的晶体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant